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Abstract: The oral bioavailability of many hydrophobic bioactive compounds found in natural food
products (such as vitamins and nutraceuticals in fruits and vegetables) is relatively low due to their
low bioaccessibility, chemical instability, or poor absorption. Most previous research has therefore
focused on the design of delivery systems to incorporate isolated bioactive compounds into food
products. However, a more sustainable and cost-effect approach to enhancing the functionality
of bioactive compounds is to leave them within their natural environment, but specifically design
excipient foods that enhance their bioavailability. Excipient foods typically do not have functionality
themselves but they have the capacity to enhance the functionality of nutrients present in natural
foods by altering their bioaccessibility, absorption, and/or chemical transformation. In this review
article we present the use of excipient nanoemulsions for increasing the bioavailability of bioactive
components from fruits and vegetables. Nanoemulsions present several advantages over other food
systems for this application, such as the ability to incorporate hydrophilic, amphiphilic, and lipophilic
excipient ingredients, high physical stability, and rapid gastrointestinal digestibility. The design,
fabrication, and application of nanoemulsions as excipient foods will therefore be described in
this article.
Keywords: excipient; nanoemulsions; bioactive; delivery; functional; oral bioavailability
1. Introduction
1.1. Concept of Excipient Foods
The functionality of bioactive compounds present in foods, dietary supplements, or drugs largely
depends on their fate in the gastrointestinal tract (GIT). The bioavailability of many health-promoting
compounds is generally low due to their low bioaccessibility, susceptibility to degradation, or poor
absorption profile. The processes that govern the oral bioavailability of bioactive compounds are
complex and include liberation of the bioactive from the ingested drug, supplement, or food [1];
solubilization within gastrointestinal fluids [2,3]; transport into or out of epithelial cells [4,5]; and/or,
biochemical or chemical transformations [6,7]. In this article, we focus on enhancing the bioavailability
of lipophilic bioactive compounds found in foods (particularly fruits and vegetables), but the same
principles could also be applied to supplements and pharmaceuticals. There is strong evidence
that the nature of foods influences the bioavailability of co-ingested bioactive compounds, thereby
altering their bioactivity. The ingredients present in the food matrix might favor or inhibit the
liberation and solubilization of functional compounds during digestion [8,9]. Therefore, there is an
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opportunity to optimize the formulation of food products to improve the bioavailability of bioactive
compounds. There are several strategies that can be used to enhance the liberation, solubilization and
absorption of bioactive compounds. Colloidal delivery systems can be used to incorporate isolated
lipophilic bioactive ingredients into food products, such as nanoemulsions, emulsions, or solid lipid
nanoparticles [10,11]. In this case, the bioactive compound is first extracted from a natural source and
it is then solubilized in a lipid phase prior to the formation of the colloidal delivery system that will
be ultimately incorporated in a food product. Alternatively, the bioactive compounds might be left
in their natural source (fruit or vegetable) and consumed along with a specific formulation able to
boost their bioactivity. In this context, the concept of excipient foods has been introduced as foods that
are specifically designed to improve the bioavailability of bioactive components [12]. Excipient foods
might or might not have an intrinsic bioactivity themselves, but when they co-ingested with other
foods they can boost the bioactivity of any bioactive compounds present.
1.2. Nanoemulsions as Excipient Foods
Nanoemulsions have been described as excellent carriers for lipophilic bioactive compounds with
enhanced properties compared to conventional emulsions. Typically, nanoemulsions are defined as
oil-in-water emulsions with a very small droplet size (r < 100 nm). Their small droplet dimensions
confer them with unique properties, such as improved physical stability, high optical clarity, and
enhanced bioavailability [13]. Due to their small droplet size, nanoemulsions have a large surface area
and can therefore interact strongly with biological components in the GIT. For instance, nanoemulsions
typically have a higher digestion rate in the gastrointestinal tract compared to conventional emulsions
since they have more binding sites available for digestive enzymes, such as lipase [14]. Moreover,
the small droplet size may favor the rapid transfer of naturally occurring hydrophobic bioactives
present in foods into the oil droplets. Thus, in this review article, we focus on describing the use
of nanoemulsions as excipient foods and how their composition and structure can be modulated to
achieve an optimal efficacy of the functional components of natural food products.
2. Excipient Foods
The relationship between the composition of foods and many health issues is well documented and
consumers are nowadays generally aware of the importance of a balanced diet. However, the lifestyle
of many modern consumers makes it difficult to ingest all of the nutrients needed to maintain normal
body functions or promote good health. The use of food products or nutraceuticals to treat health
conditions has already been described and is intended to prevent or cure certain diseases. Medical or
functional foods fall in the category of foods that are specifically designed to ameliorate human health
problems [15]. For instance, a medical food is defined by the Food and Drug Administration (FDA) as
“a food which is formulated to be consumed or administered entirely under the supervision of a physician and
which is intended for the specific dietary management of a disease or condition for which distinctive nutritional
requirements, based on recognized scientific principles, are established by medical evaluation” [15]. On the
other hand, functional foods are described as natural or processed foods that have been specifically
been fortified with bioactive compounds. Various types of functional food products already exist
in the market, such as milks fortified with vitamin D, orange juices enriched with calcium, yogurts
containing probiotics, spreads fortified with phytosterols, and breakfast cereals containingω-3 fatty
acids, vitamins, and minerals [16]. Nevertheless, the concept of designing healthier food products has
recently gone a step further to optimize the promotion of the intrinsic health properties of natural food
products. In this context, excipient foods have been introduced as foods that are able to improve the
bioactivity of foods co-ingested with them [12] (Figure 1). Thus, excipient foods do not necessarily have
bioactive properties but when ingested along with natural or processed food products they are able to
promote the release and absorption of naturally occurring bioactive compounds. Excipient foods can
be classified into two groups: (i) integrated excipient foods—the bioactive agents are dispersed into
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the excipient food formulation; (ii) non-integrated excipient foods—a bioactive-rich food is co-ingested
with an excipient food formulation (Figure 1).Nanomaterials 2016, 6, 17 3 of 15 
 
Figure 1. Schematic diagram of the difference between integrated and non-integrated excipient foods. 
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within the excipient food matrix, but for non-integrated excipient foods the bioactive component is in 
another product that is co-ingested with the excipient food. 
Conceptually, many types of foods products could potentially be designed to act as excipient 
foods. The type of product will be determined partly by the compatibility between the natural food 
and the excipient formulation. In Table 1 a number of examples are given for potential combinations 
of natural foods with high bioactive potential and excipient foods. For instance, an excipient salad 
dressing could be designed to enhance the bioavailability of carotenoids in salad vegetables. Indeed, 
there is already evidence that adding a certain amount of fat to a salad can increase the bioavailability 
of carotenoids [17]. Alternatively, an excipient sauce could be added during the cooking of vegetables, 
meat or fish. These excipient dressings or sauces may contain various food components that increase 
the bioavailability of the natural bioactive compounds present in foods, such as lipids that increase 
GIT solubility, antioxidants that inhibit chemical transformations, enzyme inhibitors that retard 
metabolism, or permeation enhancers that increase absorption. 
Table 1. Examples of potential excipient foods to be co-ingested with natural food products to 
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Dairy products 
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Fish Sauce ω-3 fatty acids 
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There are several factors that limit the oral bioavailability of bioactive compounds in foods. 
There is a need to better understand the fate of bioactive compounds during their passage through 
the GIT in order to formulate optimal excipient foods to enhance their oral bioavailability. An 
integrated approach has been recently described to explain the main factors limiting the oral 
bioavailability of bioactive compounds (Equation (1)) [18]: 
Figure 1. Schematic diagram of the difference between integrated and non-integrated excipient foods.
For integrated excipient foods the bioactive component (pharmaceutical or nutraceutical) is dispersed
within the excipient food matrix, but for non-integrated excipient foods the bioactive component is in
another product that is co-ingested with the excipient food.
Conceptually, many types of foods products could potentially be design d to act as excipient
foods. The type of prod ct will be determined pa tly by the compatibility between the natural food
and the excipient formulation. In Table 1 a number of examples are give for pote tial combinations
of natural foods with high bi active potential and excipient foods. For instance, an excipient salad
dressing could be designed to enhance the bioavailability of carotenoids in salad vegetables. Indeed,
there is already evidence that adding a certain amount of fat to a salad can increase the bioavailability
of carotenoids [17]. Alternatively, an excipient sauce could be added during the cooking of vegetables,
meat or fish. These excipient dressings or sauces may contain various food components that increase
the bioavailability of the natural bioactive compounds present in foods, such as lipids that increase GIT
solubility, antioxidants that inhibit chemical transformations, enzyme inhibitors that retard metabolism,
or permeation enhancers that increase absorption.
Table 1. Examples of potential excipient foods to be co-ingested with natural food products to enhance
the oral bioavailability of bioactive compounds.
Foo Source Compatibl Excipient Food Bioac ive Compound
Salad Salad dressing Carotenoids
Fruits and berries Cream, ice cream, yogurt Flavonoids, vitamins, coenzyme Q10
Vegetables Edible coatings, sauce Car tenoids, vitamins,phytosterols/stanols
Nuts and seeds Edible coatings, sauce Flavonoids, vitamins
Meat Sauce Conjugated linoleic aci
Dairy products (cheese) Sauce Conjugated linoleic acids
Fish Sauce ω-3 fatty acids
3. Factors Limiting the Bioavailability of Bioactive Compounds
There are several factors that limit the oral bioavailability of bioactive compounds in foods. There
is a need to better understand the fate of bioactive compounds during their passage through the GIT
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in order to formulate optimal excipient foods to enhance their oral bioavailability. An integrated
approach has been recently described to explain the main factors limiting the oral bioavailability of
bioactive compounds (Equation (1)) [18]:
BA “ B*ˆA*ˆT* (1)
Here, BA is the oral bioavailability of a certain bioactive compound, B* is the bioaccessibility,
A* is the absorption and T* is the molecular transformation. Thus, in order to maximize the oral
bioavailability of a determined molecule, one has to enhance the fraction that will be bioaccessible,
absorbed and in an active state after any changes in the molecular structure that might have occurred
during digestion (Figure 2).
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Figure 2. The overall oral bioavailability of bioactives is go rned by thr e main factors: bioac essibility;
absorption; and transformation.
The classification of bioactive compounds according to the factors limiting their oral bioavailability
has been recently been described using a nutraceutical bioavailability classification scheme
(NuBACS) [9]. In this classification scheme, the many factors that limit the bioaccessibility, absorption,
or transformation of a bioactive compound are indicated. Each compound f lls into a different
catego y depending n their behavior under GIT conditions, as well as their intrinsic pr perties.
The bioaccessibility is mainl i fluenced by the liberation of the compou d from the food matrix
(L); poor solubility in the gastrointestinal fluids (S) and possible interactions that might promote
insolubility (I). The main hurdles influencing the absorption are poor transport through the mucus
layer (ML), tight junctions (TJ) or bilayer membranes (MP), inhibition of active transporters (AT), or the
presence of efflux transporters (ET) in the epithelium cells. The transformation of bioactive compounds
into more or less active forms is mainly affected by changes in their activity due to chemical (C) or
metabolic (M) mechanisms.
The above-mentioned fact rs affecting the bioavailability have be n summ rized i Table 2.
Moreover, the m chanism of action of how nanoemulsions might overcome the natural barriers that
limit the oral bioavailability of bioactive compounds present in foods is explained later on in the
review article.
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Table 2. Examples of potential excipient foods to be co-ingested with natural food products to enhance
the oral bioavailability of bioactive compounds.
Bioaccessibility Absorption Transformation
Liberation: the bioactive must be
released from the drug,
supplement of food matrix
Mucus layer: the bioactive must be
transported across the mucus layer that
coats epithelium cells
Chemical transformation: some
bioactives undergo chemical
degradation within the GIT
Solubilization: the bioactive must
be solubilized within GIT fluids
Tight junctions: some bioactives may pass
through tight junctions separating
epithelium cells
Biochemical transformation: some
bioactives are digested or
metabolized by enzymes in the GIT
Interactions: the bioactive may
interact with other food
components
Membrane permeation: some bioactives
may be transported through the
phospholipid bilayer
Active Transport: some bioactives are
transported by active transport proteins
Efflux: some bioactives are removed from
epithelium cells by efflux proteins
4. Nanoemulsions
4.1. Formation
The formation of food-grade nanoemulsions can be divided into high-energy or low-energy
methods [13,19]. High-energy approaches utilize mechanical forces to intermingle oil and
aqueous phases and to produce small droplets, and they include high-pressure homogenization,
microfluidization, and sonication [20]. Sonicators generate high intensity ultrasonic waves that break
up the oil and water phases into small droplets mainly through cavitation effects [21]. High-pressure
homogenizers and microfluidizers also generate intense disruptive forces that can break oil droplets
down to the sub-micron range [22]. Low-energy methods utilize changes in the composition or
environment of a surfactant-oil-water system to spontaneously form small droplets, and they include
spontaneous emulsification or phase-inversion methods [23]. Low-energy methods are able to produce
nanoemulsions with simple equipment and avoid the temperature increase that is caused when using
many high-energy approaches, with similar droplet size and stability characteristics. However, high
surfactant-to-oil ratios (SOR) are needed (SOR > 0.7) when using low-energy methods to obtain small
oil droplets [24], which might be a drawback to produce excipient foods containing a minimum
amount of synthetic ingredients. In fact, the excess of surfactant used to produce nanoemulsions
by low-energy methods might form micelles and cause destabilization phenomena in food products
containing larger fat droplets [25]. Therefore, it is important to select the optimal fabrication method to
obtain excipient nanoemulsions with optimal properties suitable for each type of food product that
they will be co-ingested with. In this review article, we refer to both nanoemulsions produced by
high-energy or low-energy methods.
4.2. Characteristics
The physicochemical characteristics and composition of nanoemulsions may be modulated in
order to form excipient emulsions suitable for each target application (Figure 3) [26].
4.2.1. Droplet Size
By definition the oil droplet radius in nanoemulsions is typically below 100 nm, which leads to
properties significantly different from conventional emulsions [13]. The formation conditions, such as
homogenization pressure and cycles, can be controlled to obtain different droplet sizes. Moreover, the
emulsifier type and oil phase composition used will also determine the droplet size. Nanoemulsions
containing smaller droplet sizes have been shown to be digested by lipases more rapidly than those
containing larger droplet sizes, which is attributed to a higher surface area and therefore more binding
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sites for intestinal lipases [27]. Nanoemulsions with a faster digestibility might be used for bioactive
compounds with a faster absorption pattern, where the presence of mixed micelles is required at early
stages of the intestinal tract; whereas excipient nanoemulsions with a larger droplet size and therefore
a slower digestion rate may be preferable to improve the absorption of bioactive compounds in foods
that require a longer residence time in the GIT.
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4.2.2. Droplet Composition
Besid s the intrinsic nutritional asp cts of different types of ils and fats, the composition
of oil droplets will determine the rate and extent of oil digestibility, as well as the structure of
the mixed micelles formed after lipid digestion. Therefore, it is an important factor to take into
account when formulating excipient nanoemulsions. For instance, nanoemulsions can be formulated
with triacylglycerol oils, flavor oils, essential oils, mineral oils, or waxes. Oils with different fatty
acid compositions have been shown to give significantly different lipid digestion rates, as well as
leading to mixed micelle phases with appreciably different solubilization capacities for hydrophobic
bioactives. L ng chain triglycerides have shown to be digested more sl wly than medium or short
chain triglycerides, however, they lead to a higher bioaccessibility of carotenoids [28]. This fact was
attributed to the fact that longer chain free fatty acids lead to the generation of mixed micelles with
larger hydrophobic domains after digestion, which are able to incorporate hydrophobic bioactive
compounds with large molecular dimensions, such as carotenoids [29]. This same principle might be
applied to excipient nanoemulsions, whose oil phase composition can be specifically selected for each
individual bioactive compound.
4.2.3. Interfacial Properties
To for nanoemulsions, the use emulsifiers or surface-active molecules are required to stabilize
the small oil droplets in th aqueous phase. Typically, mulsifiers adsorb at the oil-in-water interface
thus conferring specific interfacial properties to the droplets. The oil-water i t rfaci l comp sition,
thickness, structure, or charge can be modulated using different types of emul ifiers to prepare the
nanoemulsion, or by post-homogenization methods (such as emulsifier displacement or layer-by-layer
deposition) [15]. The electrical charge of oil droplets determines their electrostatic interactions with
other oil droplets or with other charged food compounds. Consequently, it influences the aggregation
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state of the lipid droplets (stable, flocculated or coalesced), which alters the exposed surface area where
digestive enzymes adsorb. Moreover, the nature of the interface will influence the ability of bile salts
and digestive enzymes to adsorb to the lipid droplet surfaces and initiate lipolysis [30]. Moreover,
the surfactants and emulsifiers used to formulate nanoemulsions may also have an impact on the
solubilization capacity of bioactive compounds in the intestinal juices. Consequently, the selection of
an appropriate emulsifier must be optimized to ensure good bioaccessibility.
4.3. Mechanisms of Action
The design of nanoemulsions can be optimized to enhance the oral bioavailability of bioactive
compounds in the GIT altering their compositions or structures. In this section, we highlight
how discuss excipient nanoemulsions can be designed to alter the bioaccessibility, absorption, or
transformation of bioactive compounds.
4.3.1. Bioaccessibility
The bioaccessibility is defined as the amount of a bioactive agent that is present within the
gastrointestinal tract in a form suitable for absorption (mB) compared to the total amount ingested
(mTotal) (Equation (2)):
B* “ 100ˆmB{mTotal (2)
In the case of lipophilic bioactive compounds, the fraction of bioactive compound that is
solubilized in the micelle phase after the small intestine phase is considered to be potentially absorbable.
There are several strategies that can be used to increase bioaccessibility by formulating nanoemulsions,
mainly divided in efforts towards a higher release from the food matrix or a higher solubilization in
the intestinal juices.
Changes in the Bioactive Release from the Food Matrix
Depending on the type of food product, bioactives may be rapidly released from the food matrix
during digestion, or they by fully or partially retained. In solid foods, mastication may facilitate the
release of a significant fraction of bioactives. Indeed, an increase in carotenoid bioaccessibility has been
reported after mastication of mangoes [31]. However this release is not always complete and there may
still be a significant part of bioactive compounds trapped in the food matrix. Moreover, in the case of
liquid products (such as tomato juice or orange juice) the passage through the mouth is very fast and
therefore the liberation of the bioactives from the plant tissue is very low. In this sense, nanoemulsions
may present an effective way to facilitate the release of hydrophobic bioactive compounds into their
oil phase during the mouth and stomach phases, that in turn might act as reservoirs of bioactives in
the intestine. For instance, there is evidence that the addition of a nanoemulsion to curcumin powder
increases the bioaccessibility [32]. The addition of ingredients to an excipient nanoemulsion that favor
the dissociation of plant materials may also favor the release of bioactive compounds. For instance,
chelating agents might bind calcium from the plant cell wall and increase its permeability and therefore
increase the release of bioactive compounds. Also, the incorporation of proteins in the formulation of
nanoemulsions might decrease the intestinal pH due to their high buffering capacity [33]. Changes in
the pH in the intestinal phase might alter the rate and extent of the breakdown of food matrix and
therefore favor the liberation of bioactives entrapped within plant or animal tissue cells.
Solubilization in the Intestinal Fluids
The solubilization of hydrophobic bioactive compounds in the aqueous fluids within the GIT is
often an important step limiting their bioaccessibility. The co-ingestion of a lipid source has been shown
to improve the bioaccessibility of many hydrophobic bioactives by increasing their solubility in GIT
fluids [2,34,35]. This fact can be related to a number of factors that favor the solubilization of lipophilic
compounds in the GIT fluids [36]. First, the ingestion of a high amount of lipids favors the production
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of digestion enzymes and bile salts, which increases the solubilization capacity of the mixed micelle
phase. Second, the ingestion of foods with high fat levels slows down GIT transit, thereby increasing
the time for bioactives to be released from food matrices, solubilized, and absorbed [37]. Third, the
release of free fatty acids and monoacylglycerols from the initial triglyceride structure contributes to the
formation of mixed micelles that increase the solubilization capacity of the GIT fluids for hydrophobic
bioactives. Finally, the use of food-grade surfactants in excipient nanoemulsions can also increase
the solubilization capacity of intestinal fluids [38]. This type of knowledge can be used to formulate
excipient nanoemulsions that will enhance the solubility of hydrophobic bioactive compounds. Studies
have already shown that nanoemulsion-based delivery systems are able to increase the bioaccessibility
of carotenoids to a greater extent than conventional emulsions due to their higher digestibility [14].
Moreover, the bioaccessibility of other lipophilic compounds such as coenzyme Q10 can also be
enhanced by using emulsion-based delivery systems [39]. The same principle is likely to apply for
the design of excipient nanoemulsions. Nanoemulsions have a large exposed lipid surface area, and
so they are digested more rapidly and completely in the GIT. Therefore, there are more fatty acids
available to form mixed micelles to solubilize the hydrophobic bioactive compounds.
4.3.2. Absorption
After part of the bioactives have been liberated from the food matrix and also solubilized in the
intestinal fluids, they have to be transported through the lumen, mucus layer, and epithelium cells
lining the small intestine [40] (Figure 4). Therefore, intestinal cell uptake depends on the physical
barriers that the bioactive components must overcome. The absorption of a bioactive compound is
the amount that is bioaccessible and transferred into the epithelium cells (mBA) compared to the total
amount in the gastrointestinal tract (mTotal) (Equation (3)):
B* “ 100ˆmBA{mTotal (3)
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Figure 4. Schematic representation of the mechanisms involved in the absorption of bioactive
compounds in the gastrointestinal tract. The absorption of bioactive agents may be limited due
to their transport across the epithelium cell through passive, active or efflux mechanisms. Most
bioactive compounds are usually absorbed in the upper gastrointestinal tract (GIT) and therefore do
not reach the M-cells, but bioactives trapped within indigestible particles or matrices may move further
down the GIT and then encounter the M-cells.
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Increase in Mucus Layer Transport
The mucus layer is a porous hydrogel layer that coats the enterocytes in the epithelium cells.
For the bioactive compound to be transferred to the intestinal cells it has to travel across the mucus layer.
If the mixed micelles are larger than the pore size (400 nm) or strongly interact with the mucus layer,
then their transport through this layer might be significantly inhibited. For instance, nanoemulsions
can be formulated with small molecule surfactants or other stabilizers that help forming small mixed
micelles that easily penetrate through the mucus layer [41].
Increase in the Permeability of Cell Membranes
Once the bioactive has passed through the mucus layer, it may be incorporated into the intestinal
cells by either passive or active transport (Figure 4). The nature and environment of the bioactive
compound determines the absorption route taken [42–44]. Sufficiently small colloidal particles may
be able to travel through the narrow channels separating the epithelial cells known as tight junctions.
Therefore, excipient nanoemulsions could be formulated with ingredients that are capable of enlarging
the tight junctions [45] such as certain surfactants [46,47]; biopolymers [48,49], mineral ions [50], and
chelating agents [51]. Other types of bioactive compounds are transported across the epithelium cell
walls by specific or non-specific protein-transporter systems, which consist of one or more proteins
embedded in the phospholipid bilayer. Both passive and active transport can be modulated by
including excipient ingredients in nanoemulsions such as piperine [52], sucrose monoesters [53], and
rhamnolipids [54].
Efflux Inhibition
After bioactive compounds are transported into the epithelium cells they may be pumped back
into the GIT by certain efflux transporters located in the cell membranes [55,56]. Certain food
ingredients might block the efflux transporters, such as quercetin, resveratrol, and piperine that
may act as efflux inhibitors for certain pharmaceutical agents [57–60]. Efflux inhibitors might either
block binding sites on the surfaces of efflux proteins, interfere with the energy production mechanism
required for efflux or change cell membrane structure thereby altering the conformation and activity
of efflux proteins.
4.3.3. Transformation
Many bioactive compounds undergo chemical or enzymatic transformations during their passage
though the GIT, which may alter their bioavailability and bioactivity. These transformations may be
from an active to an inactive form, or vice versa. For instance, carotenoids are present in different
isomer forms in fruits and vegetables, and cis-isomers are more bioavailable than trans-isomers since
the long linear structure of trans-isomers are difficult to fit into mixed micelles [61,62]. Trans-isomers in
foods can undergo isomerization to cis-isomers, which might then be absorbed more effectively [63,64].
Consequently, it may be possible to add excipient ingredients to a nanoemulsion to enhance this
isomerization reaction. Conversely, certain types of food components under oxidation or other
degradation reactions that reduce their biological activity, e.g., carotenoids, ω-3 fatty acids, and
curcumin. In these cases, it is possible to add natural or synthetic antioxidants to inhibit their
degradation [65]. Therefore, efforts might be put in designing foods that might favor or oppose
the chemical or enzymatic conversions of bioactive compounds in the GIT.
4.4. Examples of Excipient Nanoemulsions
Recently, a number of studies have demonstrated the potential application of nanoemulsions
for enhancing the oral bioavailability of bioactive compounds in natural foods (Table 3). Different
strategies have been addressed to enhance the oral bioavailability of bioactive compounds though
increasing the bioaccessibility, the absorption, or transformation.
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Table 3. Examples of potential excipient emulsions or nanoemulsions to be co-ingested with natural
food products to enhance the oral bioavailability of bioactive compounds.
Emulsion Nutraceuticals Excipient Emulsion InfluencingNutraceuticals Bioaccessibility Reference
Corn oil emulsions Curcumin inPowdered Form
The solubility and bioaccessibility of curcumin
was significantly improved by incubating and
co-ingesting with excipient emulsion.
[32]
Corn oil emulsions Curcumin inPowdered Form
Emulsifier type and droplet size of exhibited a
significant effect on the solubility and
bioaccessibility of curcumin.
[66]
Corn oil emulsions Curcumin inPowdered Form
The bioaccessibility of curcumin depended on
oil type and concentration. [67]
Corn oil, medium chain
triglycerides or orange
oil emulsions
Carotenoids in
yellow peppers
Increased carotenoid bioacessibility from
yellow peppers when consumed with corn oil
nanoemulsions as excipient emulsions.
[68]
Olive oil emulsions
Carotenoids in
Carrot and Tomato
suspensions
Adding olive emulsions to carrot and tomato
suspensions increased carotenoid uptake in the
micellar phase.
[69]
Peanut oil emulsions Carotenoids inTomato juice
Lycopene bioaccessibility was dependent on
emulsification and emulsifier type [70]
Various emulsions Carotenoids invegetables and salads
Addition of oil to salads and vegetables
increased lycopene bioaccessibility depending
on fatty acid type
[71,72]
4.4.1. Increase in Bioaccessibility
For powdered nutraceuticals, nanoemulsions have been shown to significantly increase the
transfer of the bioactive crystalline form to the oil phase, which is directly related to an increased
solubility in the GIT fluids. For instance, Zou and co-workers [32,66] reported an increased in vitro
bioaccessibility of powdered curcumin after mixing with excipient nanoemulsions, which simulated a
salad dressing (incubation at 30 ˝C) or a cooking sauce (incubation at 100 ˝C). They found a higher
transfer of curcumin powder to the oil droplets when nanoemulsions were incubated at 100 ˝C
compared to 30 ˝C. In the case of bioactive compounds in plant-based products, lipid droplets in
nanoemulsions lipid droplets may act as a non-polar solvent that facilitates the liberation of the
hydrophobic bioactives from their original location in plant tissues [70]. In fact, the results from several
studies with different vegetables are consistent and support this statement. For example, an increase
in carotenoid bioaccessibility from yellow peppers has been found after being mixed with excipient
nanoemulsions [68]. Moreover, the solubilization of carotenoids in the micelle fraction after in vitro
digestion of carrot and tomato suspensions was significantly increased after being co-ingested with
olive oil emulsions.
There are several factors that influence the ability of excipient nanoemulsions to enhance the
bioaccessibility of bioactive compounds, such as the lipid amount, size and composition. For instance,
it is known that the higher the oil concentration in the formulation of bioactive-loaded nanoemulsions,
the higher the bioaccessibility [29]. This behavior also occurs with excipient nanoemulsions or
emulsions consumed with bioactive-rich foods. It has been reported that full-fat salad dressings
enhance the oral bioavailability of bioactive compounds to a higher extent than low-fat dressings [17].
Also, the oil composition influences the solubilization of hydrophilic nutraceuticals in the intestinal
juices, since the free fatty acids will form the non-polar domains of the mixed micelle phase. It is
known that nanoemulsions formulated with long chain triglycerides show an enhanced bioaccessibility
of hydrophobic bioactives than medium or short chain triglycerides, which is attributed to a
larger micelle structure able to accommodate the hydrophobic bioactives in their core [28,29]. This
phenomenon is important when designing excipient nanoemulsions since the same principle would
apply for nanoemulsions that are co-ingested with natural foods, as the bioactive compounds
might already be transferred into the oil phase prior to digestion. Moreover, the nanoemulsion
droplet size is an important factor that determines the rate of lipid digestion rate and mixed
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micelle formation. The smaller the droplet size, the higher the lipid hydrolysis rate and in turn
the higher the bioaccessibility [14,73]. This behavior has been also detected when designing excipient
nanoemulsions [66].
The ability of nanoemulsions to enhance the solubilization of lipophilic bioactive compounds
in intestinal juices has been demonstrated for numerous types of hydrophobic bioactive agents.
Nevertheless, the overall bioavailability of the solubilized fraction has been studied far less
frequently. Even so, some studies have shown that hydrophobic bioactive compounds encapsulated
within nanoemulsions have a higher bioavailability than those encapsulated within conventional
emulsions [74]. On the other hand, to the best of the authors’ knowledge, there have been no reports
on the improvement of the bioavailability of bioactive compounds using excipient nanoemulsions to
date. Therefore, it is important to elucidate the potential efficacy of excipient nanoemulsions using
animal and human feeding studies.
4.4.2. Changes in Absorption and Transformation
Strategies developed to enhance the absorption or transformation of bioactive compounds in the
gastrointestinal tract using excipient nanoemulsions is currently scarce, but it is certainly an important
topic that should be studied more to improve the ability of excipient nanoemulsions to boost the
oral bioavailability of bioactive compounds. For instance, it is known that oil type influences the
absorption of bioactives in the gastrointestinal tract as they influence the nature of the chylomicrons
formed [75,76]. Oleic acid has also been shown to be an effective inhibitor of efflux mechanisms [77],
which may help increase the absorption of certain bioactive compounds. Moreover, the intestinal
absorption of hydrophobic bioactives has been enhanced by their ingestion along with piperine from
black pepper, which alters the epithelium cell transport mechanisms [78]. Regarding the molecular
and structural transformation of bioactive compounds during their passage though the intestinal
tract, efforts have been made to design structures to protect them from oxidation and degradation.
For instance, the presence of chelating agents, such as EDTA, or antioxidants, such as tocopherol, has
shown to decrease the degradation rate of astaxanthin [79]. This would also be valid for the design
of excipient nanoemulsions, which might contain those ingredients either in the aqueous or lipid
phases and would protect the natural bioactive compounds in foods. The type of antioxidant used to
formulate excipient nanoemulsions might be specifically selected depending on the type of bioactive
compound to be protected. For instance, lipophilic bioactive compounds such as tocopherols can be
included in the lipid phase to prevent degradation of carotenoids. On the other hand, chelating agents
(such as EDTA) can be incorporated into the aqueous phase to bind with and inactivate pro-oxidant
metal ions (such as iron). Thus, even though the current knowledge regarding the exact mechanism
about how to improve the oral bioavailability of different natural bioactives in food is still to be fully
elucidated, the available information clearly highlights the greater potential of nanoemulsions as
excipient foods.
5. Conclusions
In this review article we focused on describing the potential advantages of using nanoemulsions
as excipient foods to increase the oral bioavailability of naturally occurring bioactive compounds. It is
important to understand the fate of health-related food components in the gastrointestinal tract so as
to formulate nanoemulsions with specific structures and compositions known to boost bioavailability
and maintain bioactivity. Excipient nanoemulsions may be used to enhance the bioaccessibility
and absorption of bioactive compounds in the gastrointestinal tract, as well as controlling their
molecular form to ensure they are in the most bioactive state. In certain applications, nanoemulsions
have advantages over conventional emulsions because their small droplet size and higher surface
area leads to rapid digestion and mixed micelle formation. The co-ingestion of nanoemulsions
with foods, supplements or drugs may be a useful method to optimize the uptake of hydrophobic
bioactives. Nevertheless, there is still a need to unravel the complex physicochemical and physiological
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processes involved when excipient nanoemulsions and foods pass through the GIT. This information
might be highly valuable for the food and pharmaceutical sector to optimize the bioavailability of
bioactive compounds.
Acknowledgments: This material is based upon work supported by the Cooperative State Research, Extension,
Education Service, United State Department of Agriculture, Massachusetts Agricultural Experiment Station
(Project No. 831) and by the United States Department of Agriculture, NRI Grants (2011-03539, 2013-03795,
and 2014-67021).
Author Contributions: David Julian McClements and Laura Salvia-Trujillo developed the idea and structure of
the review article. Salvia-Trujillo wrote the paper using material supplied by McClements. Olga Martín-Belloso
contributed with the revision of the manuscript. All authors have given approval to the final version of
the manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Moelants, K.R.N.; Lemmens, L.; Vandebroeck, M.; van Buggenhout, S.; van Loey, A.M.; Hendrickx, M.E.
Relation between Particle Size and Carotenoid Bioaccessibility in Carrot- and Tomato-Derived Suspensions.
J. Agric. Food Chem. 2012, 60, 11995–12003. [CrossRef] [PubMed]
2. Porter, C.J.H.; Trevaskis, N.L.; Charman, W.N. Lipids and lipid-based formulations: Optimizing the oral
delivery of lipophilic drugs. Nat. Rev. Drug Discov. 2007, 6, 231–248. [CrossRef] [PubMed]
3. Pouton, C.W.; Porter, C.J. Formulation of lipid-based delivery systems for oral administration: Materials,
methods and strategies. Adv. Drug Deliv. Rev. 2008, 60, 625–637. [CrossRef] [PubMed]
4. Fleisher, D.; Li, C.; Zhou, Y.; Pao, L.H.; Karim, A. Drug, meal and formulation interactions influencing
drug absorption after oral administration—Clinical implications. Clin. Pharmacokinet. 1999, 36, 233–254.
[CrossRef] [PubMed]
5. Martinez, M.N.; Amidon, G.L. A mechanistic approach to understanding the factors affecting drug
absorption: A review of fundamentals. J. Clin. Pharmacol. 2002, 42, 620–643. [CrossRef] [PubMed]
6. D’Ambrosio, D.N.; Clugston, R.D.; Blaner, W.S. Vitamin A Metabolism: An Update. Nutrients 2011, 3, 63–103.
[CrossRef] [PubMed]
7. Fernandez-Garcia, E.; Carvajal-Lerida, I.; Jaren-Galan, M.; Garrido-Fernandez, J.; Perez-Galvez, A.;
Hornero-Mendez, D. Carotenoids bioavailability from foods: From plant pigments to efficient biological
activities. Food Res. Int. 2012, 46, 438–450. [CrossRef]
8. Augustin, M.A.; Sanguansri, L. Challenges and Solutions to Incorporation of Nutraceuticals in Foods.
Annu. Rev. Food Sci. Technol. 2015, 6, 463–477. [CrossRef] [PubMed]
9. McClements, D.J.; Li, F.; Xiao, H. The Nutraceutical Bioavailability Classification Scheme: Classifying
Nutraceuticals According to Factors Limiting Their Oral Bioavailability. Annu. Rev. Food Sci. Technol. 2015, 6,
299–327. [CrossRef] [PubMed]
10. McClements, D.J.; Li, Y. Structured emulsion-based delivery systems: Controlling the digestion and release
of lipophilic food components. Adv. Colloid Interface Sci. 2010, 159, 213–228. [CrossRef] [PubMed]
11. Porter, C.J.H.; Pouton, C.W.; Cuine, J.F.; Charman, W.N. Enhancing intestinal drug solubilisation using
lipid-based delivery systems. Adv. Drug Deliv. Rev. 2008, 60, 673–691. [CrossRef] [PubMed]
12. McClements, D.J.; Xiao, H. Excipient foods: Designing food matrices that improve the oral bioavailability of
pharmaceuticals and nutraceuticals. Food Funct. 2014, 5, 1320–1333. [CrossRef] [PubMed]
13. McClements, D.J. Edible nanoemulsions: Fabrication, properties, and functional performance. Soft Matter
2011, 7, 2297–2316. [CrossRef]
14. Salvia-Trujillo, L.; Qian, C.; Martín-Belloso, O.; McClements, D.J. Influence of particle size on lipid digestion
andβ-carotene bioaccessibility in emulsions and nanoemulsions. Food Chem. 2013, 141, 1472–1480. [CrossRef]
[PubMed]
15. McClements, D.J.; Decker, E.A.; Park, Y.; Weiss, J. Structural Design Principles for Delivery of Bioactive
Components in Nutraceuticals and Functional Foods. Crit. Rev. Food Sci. Nutr. 2009, 49, 577–606. [CrossRef]
[PubMed]
16. Bigliardi, B.; Galati, F. Innovation trends in the food industry: The case of functional foods. Trends Food
Sci. Technol. 2013, 31, 118–129. [CrossRef]
Nanomaterials 2016, 6, 17 13 of 16
17. Brown, M.J.; Ferruzzi, M.G.; Nguyen, M.L.; Cooper, D.A.; Eldridge, A.L.; Schwartz, S.J.; White, W.S.
Carotenoid bioavailability is higher from salads ingested with full-fat than with fat-reduced salad dressings
as measured with electrochemical detection. Am. J. Clin. Nutr. 2004, 80, 396–403. [PubMed]
18. McClements, D.J. Utilizing food effects to overcome challenges in delivery of lipophilic bioactives: Structural
design of medical and functional foods. Expert Opin. Drug Deliv. 2013, 10, 1621–1632. [CrossRef] [PubMed]
19. Tadros, T.; Izquierdo, R.; Esquena, J.; Solans, C. Formation and stability of nano-emulsions. Adv. Colloid
Interface Sci. 2004, 108, 303–318. [CrossRef] [PubMed]
20. Abbas, S.; Hayat, K.; Karangwa, E.; Bashari, M.; Zhang, X.M. An Overview of Ultrasound-Assisted
Food-Grade Nanoemulsions. Food Eng. Rev. 2013, 5, 139–157. [CrossRef]
21. Salvia-Trujillo, L.; Rojas-Graü, M.A.; Soliva-Fortuny, R.; Martín-Belloso, O. Impact of microfluidization
or ultrasound processing on the antimicrobial activity against Escherichia coli of lemongrass oil-loaded
nanoemulsions. Food Control 2014, 37, 292–297. [CrossRef]
22. Qian, C.; McClements, D.J. Formation of nanoemulsions stabilized by model food-grade emulsifiers using
high-pressure homogenization: Factors affecting particle size. Food Hydrocoll. 2011, 25, 1000–1008. [CrossRef]
23. McClements, D.J.; Rao, J. Food-Grade Nanoemulsions: Formulation, Fabrication, Properties, Performance,
Biological Fate, and Potential Toxicity. Crit. Rev. Food Sci. Nutr. 2011, 51, 285–330. [CrossRef] [PubMed]
24. Ostertag, F.; Weiss, J.; McClements, D.J. Low-energy formation of edible nanoemulsions: Factors influencing
droplet size produced by emulsion phase inversion. J. Colloid Interface Sci. 2012, 388, 95–102. [CrossRef]
[PubMed]
25. Salvia-Trujillo, L.; McClements, D.J. Influence of Nanoemulsion Addition on the Stability of Conventional
Emulsions. Food Biophys. 2015. [CrossRef]
26. McClements, D.J.; Xiao, H. Potential biological fate of ingested nanoemulsions: Influence of particle
characteristics. Food Funct. 2012, 3, 202–220. [CrossRef] [PubMed]
27. Li, Y.; McClements, D.J. New Mathematical Model for Interpreting pH-Stat Digestion Profiles: Impact of
Lipid Droplet Characteristics on in Vitro Digestibility. J. Agric. Food Chem. 2010, 58, 8085–8092. [CrossRef]
[PubMed]
28. Qian, C.; Decker, E.A.; Xiao, H.; McClements, D.J. Nanoemulsion delivery systems: Influence of carrier oil
on β-carotene bioaccessibility. Food Chem. 2012, 135, 1440–1447. [CrossRef] [PubMed]
29. Salvia-Trujillo, L.; Qian, C.; Martín-Belloso, O.; McClements, D.J. Modulating β-carotene bioaccessibility
by controlling oil composition and concentration in edible nanoemulsions. Food Chem. 2013, 139, 878–884.
[CrossRef] [PubMed]
30. Couedelo, L.; Amara, S.; Lecomte, M.; Meugnier, E.; Monteil, J.; Fonseca, L.; Pineau, G.; Cansell, M.;
Carriere, F.; Michalski, M.C.; et al. Impact of various emulsifiers on ALA bioavailability and chylomicron
synthesis through changes in gastrointestinal lipolysis. Food Funct. 2015, 6, 1726–1735. [CrossRef] [PubMed]
31. Low, D.Y.; D’Arcy, B.; Gidley, M.J. Mastication effects on carotenoid bioaccessibility from mango fruit tissue.
Food Res. Int. 2015, 67, 238–246. [CrossRef]
32. Zou, L.Q.; Liu, W.; Liu, C.M.; Xiao, H.; McClements, D.J. Utilizing Food Matrix Effects To Enhance
Nutraceutical Bioavailability: Increase of Curcumin Bioaccessibility Using Excipient Emulsions. J. Agric.
Food Chem. 2015, 63, 2052–2062. [CrossRef] [PubMed]
33. Kalantzi, L.; Goumas, K.; Kalioras, V.; Abrahamsson, B.; Dressman, J.B.; Reppas, C. Characterization of the
human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies.
Pharm. Res. 2006, 23, 165–176. [CrossRef] [PubMed]
34. Charman, W.N.; Porter, C.J.H.; Mithani, S.; Dressman, J.B. Physicochemical and physiological mechanisms
for the effects of food on drug absorption: The role of lipids and pH. J. Pharm. Sci. 1997, 86, 269–282.
[CrossRef] [PubMed]
35. Williams, H.D.; Trevaskis, N.L.; Charman, S.A.; Shanker, R.M.; Charman, W.N.; Pouton, C.W.; Porter, C.J.H.
Strategies to Address Low Drug Solubility in Discovery and Development. Pharmacol. Rev. 2013, 65, 315–499.
[CrossRef] [PubMed]
36. Varum, F.J.O.; Hatton, G.B.; Basit, A.W. Food, physiology and drug delivery. Int. J. Pharm. 2013, 457, 446–460.
[CrossRef] [PubMed]
37. Kossena, G.A.; Charman, W.N.; Wilson, C.G.; O’Mahony, B.; Lindsay, B.; Hempenstall, J.M.; Davison, C.L.;
Crowley, P.J.; Porter, C.J.H. Low dose lipid formulations: Effects on gastric emptying and biliary secretion.
Pharm. Res. 2007, 24, 2084–2096. [CrossRef] [PubMed]
Nanomaterials 2016, 6, 17 14 of 16
38. Verrijssen, T.A.J.; Smeets, K.H.G.; Christiaens, S.; Palmers, S.; van Loey, A.M.; Hendrickx, M.E. Relation
between in vitro lipid digestion and β-carotene bioaccessibility in β-carotene-enriched emulsions with
different concentrations of L-α-phosphatidylcholine. Food Res. Int. 2015, 67, 60–66. [CrossRef]
39. Cho, H.T.; Salvia-Trujillo, L.; Kim, J.; Park, Y.; Xiao, H.; McClements, D.J. Droplet size and composition
of nutraceutical nanoemulsions influences bioavailability of long chain fatty acids and Coenzyme Q10.
Food Chem. 2014, 156, 117–122. [CrossRef] [PubMed]
40. Porter, C.J.H.; Charman, W.N. Intestinal lymphatic drug transport: An update. Adv. Drug Deliv. Rev. 2001,
50, 61–80. [CrossRef]
41. Lafitte, G.; Thuresson, K.; Soderman, O. Diffusion of nutrients molecules and model drug carriers through
mucin layer investigated by magnetic resonance imaging with chemical shift resolution. J. Pharm. Sci. 2007,
96, 258–263. [CrossRef] [PubMed]
42. des Rieux, A.; Fievez, V.; Garinot, M.; Schneider, Y.J.; Preat, V. Nanoparticles as potential oral delivery
systems of proteins and vaccines: A mechanistic approach. J. Control. Release 2006, 116, 1–27. [CrossRef]
[PubMed]
43. Ensign, L.M.; Cone, R.; Hanes, J. Oral drug delivery with polymeric nanoparticles: The gastrointestinal
mucus barriers. Adv. Drug Deliv. Rev. 2012, 64, 557–570. [CrossRef] [PubMed]
44. Bohdanowicz, M.; Grinstein, S. Role of phospholipids in endocytosis, phagocytosis, and macropinocytosis.
Physiol. Rev. 2013, 93, 69–106. [CrossRef] [PubMed]
45. Maher, S.; Brayden, D.J.; Feighery, L.; McClean, S. Cracking the junction: Update on the progress of
gastrointestinal absorption enhancement in the delivery of poorly absorbed drugs. Crit. Rev. Ther. Drug
Carr. Syst. 2008, 25, 117–168. [CrossRef]
46. Buyukozturk, F.; Benneyan, J.C.; Carrier, R.L. Impact of emulsion-based drug delivery systems on intestinal
permeability and drug release kinetics. J. Control. Release 2010, 142, 22–30. [CrossRef] [PubMed]
47. Gupta, V.; Hwang, B.H.; Doshi, N.; Mitragotri, S. A permeation enhancer for increasing transport of
therapeutic macromolecules across the intestine. J. Control. Release 2013, 172, 541–549. [CrossRef] [PubMed]
48. Chen, M.C.; Mi, F.L.; Liao, Z.X.; Hsiao, C.W.; Sonaje, K.; Chung, M.F.; Hsu, L.W.; Sung, H.W. Recent advances
in chitosan-based nanoparticles for oral delivery of macromolecules. Adv. Drug Deliv. Rev. 2013, 65, 865–879.
[CrossRef] [PubMed]
49. Pillay, V.; Hibbins, A.R.; Choonara, Y.E.; du Toit, L.C.; Kumar, P.; Ndesendo, V.M.K. Orally Administered
Therapeutic Peptide Delivery: Enhanced Absorption Through the Small Intestine Using Permeation
Enhancers. Int. J. Pept. Res. Ther. 2012, 18, 259–280. [CrossRef]
50. Wang, X.X.; Valenzano, M.C.; Mercado, J.M.; Zurbach, E.P.; Mullin, J.M. Zinc Supplementation Modifies
Tight Junctions and Alters Barrier Function of CACO-2 Human Intestinal Epithelial Layers. Dig. Dis. Sci.
2013, 58, 77–87. [CrossRef] [PubMed]
51. Lemmer, H.J.R.; Hamman, J.H. Paracellular drug absorption enhancement through tight junction modulation.
Expert Opin. Drug Deliv. 2013, 10, 103–114. [CrossRef] [PubMed]
52. Dudhatra, G.B.; Mody, S.K.; Awale, M.M.; Patel, H.B.; Modi, C.M.; Kumar, A.; Kamani, D.R.; Chauhan, B.N.
A Comprehensive Review on Pharmacotherapeutics of Herbal Bioenhancers. Sci. World J. 2012, 2012.
[CrossRef] [PubMed]
53. Yamamoto, A.; Katsumi, H.; Kusamori, K.; Sakane, T. Improvement of Intestinal Absorption of Poorly
Absorbable Drugs by Various Sugar Esters. Yakugaku Zasshi-J. Pharm. Soc. Jpn. 2014, 134, 47–53. [CrossRef]
54. Jiang, L.F.; Long, X.W.; Meng, Q. Rhamnolipids enhance epithelial permeability in CACO-2 monolayers.
Int. J. Pharm. 2013, 446, 130–135. [CrossRef] [PubMed]
55. Fasinu, P.; Pillay, V.; Ndesendo, V.M.K.; du Toit, L.C.; Choonara, Y.E. Diverse approaches for the enhancement
of oral drug bioavailability. Biopharm. Drug Dispos. 2011, 32, 185–209. [CrossRef] [PubMed]
56. Constantinides, P.P.; Wasan, K.M. Lipid formulation strategies for enhancing intestinal transport and
absorption of P-glycoprotein (P-gp) substrate drugs: In vitro/in vivo case studies. J. Pharm. Sci. 2007, 96,
235–248. [CrossRef] [PubMed]
57. Choi, J.S.; Choi, B.C.; Kang, K.W. Effect of resveratrol on the pharmacokinetics of oral and intravenous
nicardipine in rats: Possible role of P-glycoprotein inhibition by resveratrol. Pharmazie 2009, 64, 49–52.
[PubMed]
58. Kang, M.J.; Cho, J.Y.; Shim, B.H.; Kim, D.K.; Lee, J. Bioavailability enhancing activities of natural compounds
from medicinal plants. J. Med. Plants Res. 2009, 3, 1204–1211.
Nanomaterials 2016, 6, 17 15 of 16
59. Challa, V.R.; Babu, P.R.; Challa, S.R.; Johnson, B.; Maheswari, C. Pharmacokinetic interaction study between
quercetin and valsartan in rats and in vitro models. Drug Dev. Ind. Pharm. 2013, 39, 865–872. [CrossRef]
[PubMed]
60. Jin, M.J.; Han, H.K. Effect of Piperine, a Major Component of Black Pepper, on the Intestinal Absorption
of Fexofenadine and Its Implication on Food-Drug Interaction. J. Food Sci. 2010, 75, H93–H96. [CrossRef]
[PubMed]
61. Ferruzzi, M.G.; Lumpkin, J.L.; Schwartz, S.J.; Failla, M. Digestive stability, micellarization, and uptake of
β-carotene isomers by CACO-2 human intestinal cells. J. Agric. Food Chem. 2006, 54, 2780–2785. [CrossRef]
[PubMed]
62. Boileau, A.C.; Merchen, N.R.; Wasson, K.; Atkinson, C.A.; Erdman, J.W. Cis-lycopene is more bioavailable
than trans-lycopene in vitro and in vivo in lymph-cannulated ferrets. J. Nutr. 1999, 129, 1176–1181. [PubMed]
63. Cooperstone, J.L.; Ralston, R.A.; Riedl, K.M.; Haufe, T.C.; Schweiggert, R.M.; King, S.A.; Timmers, C.D.;
Francis, D.M.; Lesinski, G.B.; Clinton, S.K.; et al. Enhanced bioavailability of lycopene when consumed as
cis-isomers from tangerine compared to red tomato juice, a randomized, cross-over clinical trial. Mol. Nutr.
Food Res. 2015, 59, 658–669. [CrossRef] [PubMed]
64. Richelle, M.; Sanchez, B.; Tavazzi, I.; Lambelet, P.; Bortlik, K.; Williamson, G. Lycopene isomerisation takes
place within enterocytes during absorption in human subjects. Br. J. Nutr. 2010, 103, 1800–1807. [CrossRef]
[PubMed]
65. McClements, D.J.; Decker, E.A. Lipid oxidation in oil-in-water emulsions: Impact of molecular environment
on chemical reactions in heterogeneous food systems. J. Food Sci. 2000, 65, 1270–1282. [CrossRef]
66. Zou, L.Q.; Zheng, B.J.; Liu, W.; Liu, C.M.; Xiao, H.; McClements, D.J. Enhancing nutraceutical bioavailability
using excipient emulsions: Influence of lipid droplet size on solubility and bioaccessibility of powdered
curcumin. J. Funct. Foods 2015, 15, 72–83. [CrossRef]
67. Ahmed, K.; Li, Y.; McClements, D.J.; Xiao, H. Nanoemulsion- and emulsion-based delivery systems for
curcumin: Encapsulation and release properties. Food Chem. 2012, 132, 799–807. [CrossRef]
68. Liu, X.; Bi, J.F.; Xiao, H.; McClements, D.J. Increasing Carotenoid Bioaccessibility from Yellow Peppers Using
Excipient Emulsions: Impact of Lipid Type and Thermal Processing. J. Agric. Food Chem. 2015, 63, 8534–8543.
[CrossRef] [PubMed]
69. Moelants, K.R.N.; Cardinaels, R.; Jolie, R.P.; Verrijssen, T.A.J.; van Buggenhout, S.; Zumalacarregui, L.M.;
van Loey, A.M.; Moldenaers, P.; Hendrickx, M.E. Relation Between Particle Properties and Rheological
Characteristics of Carrot-Derived Suspensions. Food Bioprocess Technol. 2013, 6, 1127–1143. [CrossRef]
70. Degrou, A.; Georgé, S.; Renard, C.M.G.C.; Page, D. Physicochemical parameters that influence carotenoids
bioaccessibility from a tomato juice. Food Chem. 2013, 136, 435–441. [CrossRef] [PubMed]
71. Huo, T.; Ferruzzi, M.G.; Schwartz, S.J.; Failla, M.L. Impact of fatty acyl composition and quantity of
triglycerides on bloaccessibility of dietary carotenoids. J. Agric. Food Chem. 2007, 55, 8950–8957. [CrossRef]
[PubMed]
72. Nagao, A.; Kotake-Nara, E.; Hase, M. Effects of Fats and Oils on the Bioaccessibility of Carotenoids and
Vitamin E in Vegetables. Biosci. Biotechnol. Biochem. 2013, 77, 1055–1060. [CrossRef] [PubMed]
73. Ha, T.V.A.; Kim, S.; Choi, Y.; Kwak, H.-S.; Lee, S.J.; Wen, J.; Oey, I.; Ko, S. Antioxidant activity and
bioaccessibility of size-different nanoemulsions for lycopene-enriched tomato extract. Food Chem. 2015, 178,
115–121. [CrossRef] [PubMed]
74. Yu, H.; Huang, Q. Improving the Oral Bioavailability of Curcumin Using Novel Organogel-Based
Nanoemulsions. J. Agric. Food Chem. 2012, 60, 5373–5379. [CrossRef] [PubMed]
75. Yao, M.F.; Chen, J.J.; Zheng, J.K.; Song, M.Y.; McClements, D.J.; Xiao, H. Enhanced lymphatic transport of
bioactive lipids: Cell culture study of polymethoxyflavone incorporation into chylomicrons. Food Funct.
2013, 4, 1662–1667. [CrossRef] [PubMed]
76. Yao, M.F.; Xiao, H.; McClements, D.J. Delivery of Lipophilic Bioactives: Assembly, Disassembly, and
Reassembly of Lipid Nanoparticles. Annu. Rev. Food Sci. Technol. 2014, 5, 53–81. [CrossRef] [PubMed]
77. Aspenstrom-Fagerlund, B.; Tallkvist, J.; Ilback, N.G.; Glynn, A.W. Oleic acid decreases BCRP mediated efflux
of mitoxantrone in CACO-2 cell monolayers. Food Chem. Toxicol. 2012, 50, 3635–3645. [CrossRef] [PubMed]
Nanomaterials 2016, 6, 17 16 of 16
78. Han, H.K. The effects of black pepper on the intestinal absorption and hepatic metabolism of drugs.
Expert Opin. Drug Metab. Toxicol. 2011, 7, 721–729. [CrossRef] [PubMed]
79. Tamjidi, F.; Shahedi, M.; Varshosaz, J.; Nasirpour, A. EDTA and α-tocopherol improve the chemical stability
of astaxanthin loaded into nanostructured lipid carriers. Eur. J. Lipid Sci. Technol. 2014, 116, 968–977.
[CrossRef]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons by Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
